Viking Therapeutics, Inc. (VKTX) Reaches $8.24 After 3.00% Up Move; Malvern Bancorp (MLVF) Has 3.57 Sentiment

Viking Therapeutics, Inc. (NASDAQ:VKTX) Logo

Malvern Bancorp Inc (MLVF) investors sentiment increased to 3.57 in 2018 Q4. It’s up 2.68, from 0.89 in 2018Q3. The ratio is positive, as 25 institutional investors increased or opened new positions, while 7 reduced and sold holdings in Malvern Bancorp Inc. The institutional investors in our database now hold: 9.40 million shares, up from 3.89 million shares in 2018Q3. Also, the number of institutional investors holding Malvern Bancorp Inc in top ten positions was flat from 2 to 2 for the same number . Sold All: 1 Reduced: 6 Increased: 20 New Position: 5.

The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) is a huge mover today! The stock increased 3.39% or $0.27 during the last trading session, reaching $8.24. About 715,520 shares traded. Viking Therapeutics, Inc. (NASDAQ:VKTX) has risen 39.20% since May 14, 2018 and is uptrending. It has outperformed by 34.83% the S&P500. Some Historical VKTX News: 07/03/2018 Viking Therapeutics 4Q Loss/Shr 14c; 09/05/2018 – Viking Therapeutics: VK2809 Proof-Of-Concept Study in Glycogen Storage Disease Type Ia Expected to Begin This Qtr; 07/03/2018 – $VKTX Ph2 NAFLD data pushed back from 1H18 to 2H18. -; 23/04/2018 – DJ Viking Therapeutics Inc, Inst Holders, 1Q 2018 (VKTX); 19/03/2018 – Viking Therapeutics at Investor Day Hosted By H.C. Wainwright; 09/05/2018 – Viking Therapeutics 1Q Loss/Shr 10c; 26/03/2018 – Viking Therapeutics Coverage Assumed by H.C. Wainwright at Buy; 07/03/2018 – VIKING: VK5211 TRIAL ACHIEVES PRIMARY, SECONDARY ENDPOINTS; 15/05/2018 – Arrowmark Partners Buys 3.2% Position in Viking Therapeutics; 09/05/2018 – Viking Therapeutics: VK2809 Phase 2 Fatty Liver and Hypercholesterolemia Study Enrolling, Results Expected 2H 2018The move comes after 5 months positive chart setup for the $593.67 million company. It was reported on May, 14 by We have $8.49 PT which if reached, will make NASDAQ:VKTX worth $17.81M more.

More notable recent Malvern Bancorp, Inc. (NASDAQ:MLVF) news were published by: which released: “Malvern Bancorp, Inc. Announces Malvern Bank, NA, Advisory Board for Mainline, Paoli, PA – Nasdaq” on May 13, 2019, also with their article: “Malvern Bancorp, Inc. Reports Second Fiscal Quarter 2019 Results – GlobeNewswire” published on May 01, 2019, published: “In fast-growth mode, Malvern Bancorp targeting Delaware, Quakertown – Philadelphia Business Journal” on May 03, 2019. More interesting news about Malvern Bancorp, Inc. (NASDAQ:MLVF) were released by: and their article: “Buying The 30% Drop In Malvern Bancorp – Seeking Alpha” published on December 05, 2018 as well as‘s news article titled: “Malvern Bancorp, Inc. Appoints Jamie Barrett to Its Board and Acknowledges Board Retirement – GlobeNewswire” with publication date: April 01, 2019.

Malvern Bancorp, Inc. operates as the holding firm for Malvern Federal Savings Bank that provides various banking services and products to consumer and business clients in Pennsylvania. The company has market cap of $155.83 million. The firm offers checking accounts, retirement accounts, money market accounts, time and savings accounts, interest and non-interest bearing accounts, NOW accounts, and CDARS/ICS reciprocal deposits; and debit and credit card, wire transfer, automated teller, Internet banking, ACH origination, safe deposit box, telephone banking, and mobile banking services. It has a 16.23 P/E ratio. It also provides residential mortgage loans, such as one class and one-to four-family first lien residential mortgage loans; residential and commercial construction loans, and land loans; commercial loans, including commercial real estate loans, multi-family real estate loans, industrial loans, and commercial business loans; and consumer loans, such as home equity lines of credit, second mortgage loans, and unsecured consumer lines of credit.

Seidman Lawrence B holds 9.59% of its portfolio in Malvern Bancorp, Inc. for 619,782 shares. Clover Partners L.P. owns 152,215 shares or 5.21% of their US portfolio. Moreover, Fj Capital Management Llc has 1.72% invested in the company for 748,000 shares. The Virginia-based Ejf Capital Llc has invested 1.47% in the stock. Banc Funds Co Llc, a Illinois-based fund reported 518,009 shares.

The stock increased 0.79% or $0.16 during the last trading session, reaching $20.3. About 51 shares traded. Malvern Bancorp, Inc. (MLVF) has declined 12.55% since May 14, 2018 and is downtrending. It has underperformed by 16.92% the S&P500. Some Historical MLVF News: 25/04/2018 – Malvern Bancorp 2Q EPS 31c; 16/05/2018 – Malvern International PLC Acquisition & Placing; 27/04/2018 – Malvern International 2017 Pretax Loss Narrows By 47%; 20/04/2018 DJ Malvern Bancorp Inc, Inst Holders, 1Q 2018 (MLVF)

Among 4 analysts covering Viking Therapeutics (NASDAQ:VKTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics has $40 highest and $10 lowest target. $23.40’s average target is 183.98% above currents $8.24 stock price. Viking Therapeutics had 11 analyst reports since November 19, 2018 according to SRatingsIntel. On Thursday, March 14 the stock rating was maintained by Maxim Group with “Buy”. The company was maintained on Thursday, March 14 by Raymond James. The company was initiated on Friday, February 22 by Leerink Swann. As per Thursday, March 14, the company rating was maintained by FBR Capital. The rating was upgraded by Raymond James to “Strong Buy” on Monday, November 19. H.C. Wainwright maintained Viking Therapeutics, Inc. (NASDAQ:VKTX) rating on Thursday, March 14. H.C. Wainwright has “Buy” rating and $31 target.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. The company has market cap of $593.67 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. It currently has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

More notable recent Viking Therapeutics, Inc. (NASDAQ:VKTX) news were published by: which released: “Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ? – Yahoo Finance” on May 09, 2019, also with their article: “3 Top Biotech Stocks to Buy in May – The Motley Fool” published on May 07, 2019, published: “Consolidated Research: 2019 Summary Expectations for International, Anadarko Petroleum, Viking Therapeutics, Bruker, Tech Data, and Sierra Wireless — Fundamental Analysis, Key Performance Indications – GlobeNewswire” on April 15, 2019. More interesting news about Viking Therapeutics, Inc. (NASDAQ:VKTX) were released by: and their article: “Can This NASH Stock Really Double Your Money? – Nasdaq” published on April 24, 2019 as well as‘s news article titled: “Which NASH Powerhouse Will Come Out On Top? – Seeking Alpha” with publication date: April 18, 2019.

Malvern Bancorp, Inc. (NASDAQ:MLVF) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.